## 3 Results
### Primary Part: Individual Patient-Level Data for Patients Initially Diagnosed with Stage I-III NSCLC
#### 3.1.2 Patient Characteristics
\begin{table}
\begin{tabular}{l c c c c} \hline \hline  & \multicolumn{2}{c}{**Overall**} & \multirow{2}{*}{**Stage I (N = 115)**} & \multirow{2}{*}{**Stage II (N = 98)**} & \multicolumn{2}{c}{**Stage III**} \\  & & **(N = 319)** & & **(N = 106)** \\ \hline \multirow{2}{*}{Age (years)} & median (IQR) & 69.0 (62.0–76.0) & 70.0 (62.0–76.0) & 65.5 (61.0–74.0) & 70.0 (60.0–76.0) \\  & \(<\)70, \% (n/N) & 51.7 (165/319) & 49.6 (57/115) & 58.2 (57/98) & 48.1 (51/106) \\ \hline Male, \% (n/N) & 53.3 (170/319) & 44.3 (51/115) & 53.1 (52/98) & 63.2 (67/106) \\ \hline \multirow{2}{*}{Ever smokers (current \& former), \(\ddagger\) \% (n/N)} & 92.8 (270/291) & 88.3 (91/103) & 95.6 (86/90) & 94.9 (93/98) \\  & Pack-years of smoking, median (IQR) & 40.0 (29.3–50.0) & 36.3 (20.5–50.0) & 40.0 (30.0–50.0) & 45.0 (30.0–52.5) \\ \hline BMI (kg/m\({}^{2}\)), \(\ddagger\) median (IQR) & 25.1 (22.3–28.4) & 26.0 (22.5–29.7) & 25.9 (23.4–29.0) & 24.0 (21.5–26.6) \\ \hline ECOG performance status score 0–1, \(\ddagger\) \% (n/N) & 89.3 (201/225) & 92.9 (79/85) & 90.8 (59/65) & 84.0 (63/75) \\ \hline History of other primary malignancies, \% (n/N) & 21.6 (69/319) & 25.2 (29/115) & 20.4 (20/98) & 18.9 (20/106) \\ \hline Histological disease diagnosis, \% (n/N) & 94.4 (301/319) & 98.3 (113/115) & 91.8 (90/98) & 92.5 (98/106) \\ \hline Primary tumor size (cm), \(\ddagger\) median (IQR) & 2.9 (1.8–4.7) & 1.9 (1.3–2.7) & 3.8 (2.4–4.8) & 4.7 (2.5–7.2) \\ \hline \multirow{2}{*}{Most common primary tumor histology, \(\ddagger\) \% (n/N)} & Non-squamous & 50.6 (159/314) & 63.2 (72/114) & 47.4 (46/97) & 39.8 (41/103) \\  & Squamous & 35.4 (111/314) & 21.1 (24/114) & 38.1 (37/97) & 48.5 (50/103) \\  & Adenosquamous & 11.5 (36/314) & 11.4 (13/114) & 12.4 (12/97) & 10.7 (11/103) \\ \hline Imaging testing performed, \% (n/N) & 97.2 (310/319) & 96.5 (111/115) & 98.0 (96/98) & 97.2 (103/106) \\ \hline \multirow{2}{*}{Most common \(\int\) type of testing performed, \% (n/N)} & CT & 92.9 (288/310) & 95.5 (106/111) & 95.8 (92/96) & 87.4 (90/103) \\  & PET-CT & 53.9 (167/310) & 55.9 (62/111) & 55.2 (53/96) & 50.5 (52/103) \\ \hline \multirow{2}{*}{For variables not following a normal distribution in at least one of the study subpopulations, a uniform presentation of median (IQR) was applied. \(\ddagger\) Date of confirmation of initial NSCLC diagnosis or within the preceding 30 days; \(\ddagger\) Data was missing/unknown in a subset of patients for smoking status(n = 28), \(\ddagger\) ECOG performance status(n = 94), \(\ddagger\) BM\({}^{\prime}\) (n = 34); Primary tumor size(n = 63), primary tumor histology(n = 5), and ‘type of imaging testing(n = 9). \(\ddagger\) Six more subtypes were reported in \(\leq\)2 patients each. \(\int\) Reported in \(\geq\)10.0% in any of the examined subpopulations. Abbreviations: BMI, Body Mass Index; CT, Computed Tomography; ECOG, Eastern Cooperative Oncology Group; IQR, Interquartile Range; MRI, Magnetic Resonance Imaging; N, number of patients with available data, n, number of patients with variable; NSCLC, Non-Small Cell Lung Cancer; PET-CT, Positron Emission Tomography-Computed Tomography.} \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Patient sociodemographic and clinical characteristics at initial diagnosis of early-stage NSCLC \(\ddagger\), overall and per disease stage at initial diagnosis.